Acquisition / mergerFiled on BSE ·
Sai Parenterals Limited completes acquisition of 60% stake in Prathyak Laboratories
Sai Parenteral's · Pharmaceuticals & Biotechnology
What the filing says
- Acquired 60% equity stake in Prathyak Laboratories Private Limited for ₹15 crore on October 5, 2026
- Prathyak, a research centre in Genome Valley, Hyderabad, has 28 scientists and a pipeline of 150 SKUs across 86 molecules, specializing in complex injectable and oncology products
- The remaining 40% stake may be acquired via Right of First Refusal at the same valuation, funded from internal accruals
Original filing
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Waaree Energies
Electrical Equipment
Revenue growth 40%+Margin up 2%+
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Other acquisition / merger filings this fortnight
- Acquisition / mergerKothari Petrochemicals LtdKothari Petrochemicals Ltd informs NSE on NCLT order for amalgamation scheme
- Acquisition / mergerVeranda LearningVeranda Learning announces Board constitution for J.K. Shah Commerce Education Limited
- Acquisition / mergerDr Agarwals Eye Hospital LtdDr. Agarwal’s Eye Hospital files update on Scheme of Amalgamation with Dr. Agarwal’s Health Care
- Acquisition / mergerMaithan Alloys LtdMaithan Alloys Limited acquires 2,527,000 shares of HFCL Limited on 1st Oct 2026
- Acquisition / mergerSunteck Realty LtdSunteck Realty subsidiary acquires approx. 4.5 acres land in Borivali West
- Acquisition / mergerDr Agarwal's HeaDr. Agarwal’s Health Care sanctioned NCLT merger with Dr. Agarwal’s Eye Hospital
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.